Clinical Trial

Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell Lymphoma

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this is Single-Arm, Multicenter, Open-Label Clinical Study is to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection(Axi-cel) as First-Line Therapy of High-Risk Large B-Cell Lymphoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-11.
Trial Details
NCT Number NCT06935136
Lead Sponsor Ruijin Hospital
Conditions CAR-T Cell Therapy, High-risk Large B-cell Lymphoma (LBCL)
Enrollment 60 participants
Start Date 2025-04-30
Primary Completion 2026-10-09 (estimated)
Study Completion 2028-04-09 (estimated)
Updated on ClinicalTrials.gov 2025-04-22